Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF
October 24, 2024 | 19:00
Medera Inc. today announced that its clinical-stage gene therapy subsidiary, Sardocor Corp., has successfully completed its Cohort A (low-dose). Following the recommendation of the Data Safety Monitoring Board (DSMB), dosing has begun for patients in Cohort B (high-dose).
Mobile Version